Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice
FILSPARI (sparsentan) – 2-Year Results from the Phase 3 PROTECT Study Published in The Lancet
Physiologically-Based Pharmacokinetic Model of Sparsentan to Evaluate Drug-Drug Interaction Potential
Efficacy and Safety of Sparsentan Versus Irbesartan in Patients with IgA Nephropathy (PROTECT): 2-Year Results From a Randomised Active-Controlled Phase 3 Trial
Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan vs Irbesartan in Patients With Immunoglobulin A Nephropathy
Rate of Loss of eGFR and Time-Averaged Proteinuria in IgAN Patients Progressing From Early Stage Disease to Kidney Failure
Proteinuria and kidney survival in focal segmental glomerulosclerosis (FSGS) or immunoglobulin A nephropathy (IgAN): A NEPTUNE analysis
Predictors of Major Adverse Kidney Disease Events in a Real-World Population With IgA Nephropathy
The Humanistic Burden of Rare Kidney Diseases: Understanding the Impact of Focal Segmental Glomerulosclerosis (FSGS) and Immunoglobulin A Nephropathy (IgAN) on Patients and Caregivers Study (HONUS): Results for FSGS in the United States (US)
Clinical Predictors of Major Adverse Kidney Disease Events in Patients with IgA Nephropathy
Sparsentan receptor occupancy modeling, clinical actions, and safety
Sparsentan as First-Line Treatment of Incident Patients with IgA Nephropathy: Preliminary Findings from the SPARTAN Trial
Sparsetan Reduces Proteinuria in Patients with Immunoglobulin A Nephropathy (IgAN): Interim Results of the PROTECT Study